Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)
| Autor: | Nevitha Athikari, Santosh S Waigankar, Abhinav Pednekar, Abhijit Raut, Preetham Dev, Ashishkumar Asari, Naresh Badlani, Yuvaraja B Thyavihally, Archan Khandekar |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Bladder cancer business.industry medicine.medical_treatment Incidence (epidemiology) 030232 urology & nephrology medicine.disease language.human_language Cystectomy Danish 03 medical and health sciences 0302 clinical medicine Tumor progression 030220 oncology & carcinogenesis Internal medicine medicine language Intravesical bacillus Calmette-Guerin Adverse effect business Non muscle invasive |
| Zdroj: | Asian Journal of Urology. 9:157-164 |
| ISSN: | 2214-3882 |
| Popis: | Objective To compare the differences in adverse effects and efficacy profile between bacillus Calmette-Guerin (BCG) Danish 1331 and BCG Moscow-I strain in management of non-muscle invasive bladder cancer (NMIBC). Methods Clinical data of 188 cases of NMIBC treated with BCG between 2008 and 2018 in our institute were collected prospectively and analysed retrospectively, and 114 patients who completed a minimum of 12 months of follow-up were analysed. Patient and tumor characters, strain of BCG, adverse effects and tumor progression were included for analysis. Intravesical BCG was instilled in intermediate and high-risk patients. Six weeks of induction BCG, followed by three weekly maintenance BCG at 3,6,12, 18 and 24 months was advised in high-risk patients. Results Overall 68 patients received BCG Danish 1331 strain and 46 patients received Moscow-I strain. Patient and tumor characteristics were well balanced between the two groups. The median follow-up period was 42.5 months and 34.5 months in Danish-1331 and Moscow groups, respectively. Adverse events like dropout rate, anti-tubercular treatment requirement and need of cystectomy were higher in Moscow group (n = 31, 67.4%) when compared to Danish 1331 strain (n = 33, 48.5%) (p = 0.046). On direct comparison between Danish-1331 and Moscow strain, there was similar 3-year recurrence-free survival (RFS) (80% vs. 72.9%) and 3-year progression-free survival (PFS) (96.5% vs. 97.8%). Conclusion Study results suggest no significant differences between Danish 1331 and Moscow strain in RFS and PFS, but a significantly higher incidence of moderate to severe adverse events in BCG Moscow strain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|